Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)

China flag China · Delayed Price · Currency is CNY
25.76
+1.42 (5.83%)
Sep 5, 2025, 2:45 PM CST
5.83%
Market Cap26.12B
Revenue (ttm)5.94B
Net Income (ttm)1.22B
Shares Out1.02B
EPS (ttm)1.20
PE Ratio21.42
Forward PE19.63
Dividend0.36 (1.40%)
Ex-Dividend DateMay 14, 2025
Volume19,400,600
Average Volume20,161,903
Open24.22
Previous Close24.34
Day's Range24.02 - 25.90
52-Week Range20.36 - 29.98
Beta-0.26
RSI62.85
Earnings DateOct 24, 2025

About SHE:002262

Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. It’s product portfolio includes Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc.; and Iptakalim, an anti-hypertension drug. The company’s products are used for treatment of anesthesiology, psychiatry and neurology, as well as APIs. Jiangsu Nhwa Pharmaceutical Co., LTD was founded in 1978 and is headquartered in Xuzhou, China. [Read more]

Sector Healthcare
Founded 1978
Employees 5,923
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002262
Full Company Profile

Financial Performance

In 2024, SHE:002262's revenue was 5.70 billion, an increase of 13.01% compared to the previous year's 5.04 billion. Earnings were 1.14 billion, an increase of 10.28%.

Financial Statements

News

There is no news available yet.